Back
Antibodies against the c-terminus of apoA-1 as predictors of death in the general population but not as therapeutic targets actionable through cognate peptides immunomodulation
Journal article

Antibodies against the c-terminus of apoA-1 as predictors of death in the general population but not as therapeutic targets actionable through cognate peptides immunomodulation

  • Vuilleumier, N Geneva University Hospitals, Geneva, Switzerland
  • Antiochos, P University Hospital Centre Vaudois (CHUV), Lausanne, Switzerland
  • Marques Vidal, P University Hospital Centre Vaudois (CHUV), Lausanne, Switzerland
  • Virzi, J Geneva University Hospitals, Geneva, Switzerland
  • Pagano, S Geneva University Hospitals, Geneva, Switzerland
  • Satta, N Geneva University Hospitals, Geneva, Switzerland
  • Hartley, O Geneva University Hospitals, Geneva, Switzerland
  • Brandt, K Geneva University Hospitals, Geneva, Switzerland
  • Burger, F Geneva University Hospitals, Geneva, Switzerland
  • Montecucco, F Ospedale Policlinico San Martino, Genoa, Italy
  • Kutalik, Z University of Lausanne, Lausanne, Switzerland
  • Waeber, G University Hospital Centre Vaudois (CHUV), Lausanne, Switzerland
  • Mach, F Geneva University Hospitals, Geneva, Switzerland
  • Vollenweider, P University Hospital Centre Vaudois (CHUV), Lausanne, Switzerland
Show more…
  • 2020-11-25
Published in:
  • European Heart Journal. - Oxford University Press (OUP). - 2020, vol. 41, no. Supplement_2
Cardiology and Cardiovascular Medicine
English Abstract

Aims
Autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgGs) have emerged as an independent biomarker for cardiovascular disease and mortality in humans, promote death in ApoE−/− mice, and seem to be preferentially oriented against the c-terminal part of apoA-1 (cterA1). Corresponding specific mimetic peptides were shown to reverse anti-apoA-1 IgG pro-inflammatory effects in vitro. We evaluated the association of IgG against c-terminus apoA-1 (anti-cterA1 IgGs) with all-cause mortality in the community and tested the ability of two cterA1 mimetic peptides to reverse the anti-apoA-1 IgG-induced inflammation in vitro and mortality in ApoE−/− mice.


Methods
Anti-cterA1 IgGs were measured on serum samples of 5220 consecutive participants included in the CoLaus study with median follow-up duration of 5.6 years. The primary study outcome was all-cause mortality. Two chemically engineered optimized cterA1 mimetic peptides were tested i) on HEK cells to modulate interleukin-8 (IL-8) and tumor necrosis-alpha (TNF-α) production, and ii) in apoE−/− mice exposed to 16 weeks of anti-apoA-1 IgG passive immunisation.


Results
Anti-cterA1 IgG independently predicted all-cause mortality, each standard deviation of anti-cterA1 IgG being associated with a 18% increase in mortality risk (Hazard Ratio:1.18, 95%confidence intervals:1.04–1.33; p=0.009). Both cterA1 mimetic peptides reduced the anti-apoA-1 IgG-induced inflammation in a dose-dependent manner in vitro, but did not rescue the anti-apoA-1 IgG-associated mortality in mice.


Conclusions
Anti-cterA1 IgG independently predict all-cause mortality in the general population. By failing to reverse the anti-apoA-1 IgG-induced mortality in mice, our data do not support the hypothesis that these autoantibodies could be actionable through cognate peptides immunomodulation.


Funding Acknowledgement
Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): This work was supported by a grant from the Leenaards Foundation (grant number 3698 to N.V.) by the Swiss National Science Foundation (grant number 310030-163335 to N.V.) and by the De Reuter Foundation (grant number 315112 to N.V.).
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/170987
Statistics
Document views: 30 File downloads: